Golimumab for the treatment of ankylosing spondylitis

NICE technology appraisals [TA233] Published date:

NICE recommends golimumab as a possible treatment for some adults with severe, active ankylosing spondylitis in the same circumstances as other drugs for the condition.

Who can have golimumab?

You should be able to have golimumab if:

  • you have active spinal disease as assessed on two separate occasions 12 weeks apart, and
  • you have tried at least two non-steroidal anti-inflammatory drugs (NSAIDs) but they have not worked.

When assessing your spinal disease, healthcare professionals should take into account any disabilities or difficulties in communicating you may have.

Your treatment should be started and supervised by a specialist who is experienced in diagnosing and treating ankylosing spondylitis. You should also have regular check-ups. Your treatment should continue only if your ankylosing spondylitis shows an adequate improvement. If the improvement is not maintained or if the drug stops working then treatment should be stopped.

Get involved